Abstract
No public abstract is available from the verified source records.
Open public full textPriyanka Pullarkat, Matthew Lei, Ruchi Rana, Uvette Lou, Mark Sorial, Brenna Rowen, E. Bridget Kim, Andrea Medrano, J. Erika Haydu, Jeffrey Barnes, Ephraim Hochberg, Patrick Connor Johnson, Ronald Takvorian, Julia Lynch, Katherine Thorp, Maryanne Sherburne, Brianne McGree, Josie Ford, Ronald Nemec, Catherine Cho, Jeremy S Abramson, Jacob D. Soumerai
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(20)30443-5 · 2020
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
10.1038/s41467-023-37648-w · 2023
Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study
10.1097/hs9.0000000000000919 · 2023
Obinutuzumab for the first-line treatment of follicular lymphoma
10.1056/nejmoa1614598 · 2017
Unresolved referenced work
2013
Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: GAZELLE end of induction analysis
10.1097/hs9.0000000000000860 · 2023
Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia
10.1080/10428194.2024.2341999 · 2024
Unresolved referenced work
2022
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
10.1056/nejmoa1815281 · 2019
Unresolved referenced work
2022
Increasing operational capacity and reducing costs of rituximab administration: a costing analysis
10.1002/acr2.11133 · 2020
Patient preference for a shorter infusion time of rituximab in RA [abstract]
10.1136/annrheumdis-2015-eular.2035 · 2015
Sixty-minute infusion rituximab protocol allows for safe and efficient workflow
2016
Ultrafast 30-min infusion of a rituximab biosimilar (Truxima)
10.1002/jha2.812 · 2023
Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications
10.1002/ijc.32985 · 2020
No additional external references are available.